• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

MASH

The AJMC® metabolic dysfunction-associated steatohepatitis compendium is a comprehensive resource for clinical news and expert insights for the condition, which was formerly known as nonalcoholic steatohepatitis.

Latest News

Fibroblast growth factor 21 | image credit: Juan Gärtner - stock.adobe.com
February 19th 2025
MASH-related PLC is on the rise in young adult populations, causing concerns about how to best address the metabolic disease epidemic | image credit: https://gencraft.com/generate
February 6th 2025
The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics | image credit: TAW4 - stock.adobe.com
January 28th 2025
The management of MASH for those on a GLP-1RA could benefit from the edition of efruxifermin | image credit: Crystal Light - stock.adobe.com
January 27th 2025
MASH is the inflammatory, progressed form of MASLD | image credit: Rasi - stock.adobe.com
January 20th 2025

More News

Man holding liver illustration - SewcreamStudio - stock.adobe.com

Study Highlights Increasing Global Health Burden of Liver Cancer

Rose McNulty
June 12th 2024

The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.

Read More

Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com

FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

Laura Joszt, MA
March 14th 2024

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

Read More

doctor checking liver

ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments

Laura Joszt, MA
October 11th 2022

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

Read More

fatty liver

Improving Early Detection of Nonalcoholic Steatohepatitis on Ultrasound

Rose McNulty
November 23rd 2021

A recent study aims to improve evaluation of fatty liver in ultrasound scans to increase hepatology referrals and predict significant liver fibrosis.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.